Michele M Maxwell

Author PubWeight™ 16.56^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.	Science	2007	5.49
2	SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis.	Proc Natl Acad Sci U S A	2010	2.09
3	A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.	Proc Natl Acad Sci U S A	2005	1.88
4	Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.	Proc Natl Acad Sci U S A	2006	1.73
5	A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase.	ACS Chem Biol	2011	1.17
6	Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation.	Neuromuscul Disord	2010	1.01
7	Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.	PLoS Curr	2010	0.91
8	Two approaches to drug discovery in SOD1-mediated ALS.	J Biomol Screen	2006	0.86
9	Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments.	J Biomol Screen	2007	0.83
10	Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells.	Chem Biol	2006	0.82